These benefits, along with a prior report displaying that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like actions in mice,2 support the principle of targeting ACKR3 as a unique strategy to modulate the opioid process, which could open new therapeutic avenues for opioid-connected disorders. By ticking this box and publishing https://helenn257plh6.wikistatement.com/user